EyePoint Pharmaceuticals, Inc. (NASDAQ: $EYPT) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.
Location: Canada, Saskatchewan, Watertown
Phone: +1 833-393-7646
Investors 3
| Date | Name | Website |
| - | SWK Holdin... | swkhold.co... |
| - | EW Healthc... | ewhealthca... |
| - | CRG | crglp.com |
Mentions in press and media 12
| Date | Title | Description |
| 18.08.2026 | China's Betta Pharma Hits Limit-Down After Duravyu Fails to Match Rival Eye Drug | (Yicai) Aug. 18 -- Shares of China's Betta Pharmaceuticals plunged by the daily limit today after its US partner EyePoint said a late-stage trial of their jointly developed eye disease drug Duravyu failed to show it worked at least as well ... |
| 17.08.2026 | Stocks making the biggest moves midday: EyePoint, Intuitive Machines, Workday, JetBlue & more | - |
| 07.03.2024 | EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments | - |
| 15.07.2022 | EyePoint Pharma Shares Rise 19% After Positive Data for EYP-1901 Trial | Jul 15 2022 WATERTOWN, Massachusetts—/PRNewswire/—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders,... |
| 19.11.2021 | EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering | WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye diso... |
| 19.11.2021 | EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering | WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye diso... |
| 04.10.2021 | EW Healthcare Partners Announces the Promotion of Senior Executives | Oct 04 2021 NEW YORK, New York – EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the promotion of senior executives of their investment team. • Brooks Andrews has bee... |
| 28.01.2021 | EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD | Jan 28 2021 WATERTOWN, Massachusetts (GLOBE NEWSWIRE)—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye d... |
| 21.02.2020 | EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock | Feb 21 2020 Watertown, MASSACHUSETTS—(GLOBE NEWSWIRE)—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an u... |
| 22.08.2019 | EW Healthcare Partners Raises Over $745 Million Fund 2 | Aug 22 2019 Team of Experienced Healthcare Investors and Former Healthcare Executives Will Invest in Select Healthcare Companies to Seek to Accelerate Their Revenue Growth Partner and Principals Promoted in London, New York and Palo Alto ... |
Show more